Cardiovascular disease prevention, blood pressure, cholesterol, and heart function
675 articles
A new NEJM editorial calls for broader surgical adoption of tranexamic acid, a proven blood-loss-reducing drug that remains underutilized worldwide.
A major RCT of 1,840 ICU patients finds limiting oxygen after cardiac arrest does not improve survival or functional outcomes.
A mitochondrial enzyme found upregulated in pulmonary hypertension patients triggers vascular damage through a noncanonical mechanism — and a known drug can block it.
New analysis of 3,698 post-MI patients shows elevated heart rate predicts worse outcomes, and stopping beta-blockers raises HR by 10–13 bpm.
A new study finds elevated apolipoprotein B strongly predicts reduced myocardial flow reserve, deepening its role in cardiovascular risk.
A 2025 review maps the key genetic mutations, polygenic risk scores, and emerging therapies reshaping early-onset CVD prevention.
A systematic review of 2,521 patients maps how genetic architecture shapes triglyceride severity, pancreatitis risk, and liver disease burden.
New research in Circulation explores how cardiac biomarkers may serve as early predictors of skeletal muscle deterioration.
Experts weigh in on whether right ventricular-pulmonary arterial coupling during exercise predicts outcomes in mitral regurgitation.
A completed Phase 3 RCT examines whether weekly semaglutide injections improve symptoms and body weight in heart failure patients with obesity.
A Phase 3 trial examines whether bococizumab slashes LDL in statin-treated patients at elevated cardiovascular risk.
A comprehensive review reveals the complex genetic architecture of familial hypercholesterolaemia, where polygenic and Lp(a) mechanisms explain most 'mutation-negative' cases.
